Request free information kit about shingles and the shingles vaccine at zostavax.com

Request more information

Please review the permission statement below and Merck’s privacy commitment to you.

The information you provide will be available to the Merck & Co., Inc. family of companies (collectively, “Merck”) and others working on behalf of Merck, and according to the same standards to provide the information and services you request. Personal information about you will not otherwise be disclosed for marketing purposes without your permission. Merck reviews personal information not only to provide the requested information and services but also to develop and offer additional services and communications that we believe our customers might find of interest. Merck also may use personal information to audit its resources for compliance and security purposes. For more information about how Merck protects personal information about you, please read Merck’s Internet Privacy Policy and Privacy Commitment to U.S. Patients, Consumers, and Caregivers.

ZOSTAVAX is a vaccine that can help prevent Shingles in adults 50 years of age or older.

ZOSTAVAX is given as a single shot. ZOSTAVAX cannot be used to treat Shingles, or the nerve pain that may follow Shingles, once you have it. Talk to your health care provider to see if ZOSTAVAX is right for you.

Important Safety Information

	ZOSTAVAX may not protect everyone who gets the vaccine.
	You should not get ZOSTAVAX if you are allergic to any of its ingredients, including gelatin or neomycin, have a weakened immune system, take high doses of steroids, or are pregnant or plan to become pregnant.
	ZOSTAVAX should not be given at the same time as PNEUMOVAX^®23 (Pneumococcal Vaccine Polyvalent).
	Possible side effects include redness, pain, itching, swelling, warmth, or bruising at the injection site, as well as headache.
	ZOSTAVAX contains a weakened chickenpox virus. Tell your health care provider if you will be in close contact with newborn infants, someone who may be pregnant and has not had chickenpox or been vaccinated against chickenpox, or someone who has problems with their immune system. Your health care provider can tell you what situations you may need to avoid.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please read the Patient Product Information or Prescribing Information and discuss it with your doctor or health care provider.

If you'd like to receive more information about Shingles and ZOSTAVAX, the Shingles vaccine, please fill out the following information.

*Denotes a required field.

*First Name

*Last Name

*Your E-mail Address

*Confirm Your E-mail Address

*Street Address 1

Street Address 2

*City

*State

*ZIP CODE

Year of Birth

Why?

*How would you like
to receive the kit?

By Postal Mail

By providing your name, e-mail address and other personal information, and by clicking the "Submit" button below, you agree to permit Merck, and others working on behalf of Merck, to provide the requested information described above, as well as e-mail and other communications about new resources or services related to ZOSTAVAX and specific medical options and to use your information for market research purposes.

Merck, and others working on behalf of Merck, may provide additional materials about other Merck products and services, health conditions, and topics that Merck believes you might find useful. You also may be asked for your opinion about programs and materials. By checking the box below, you agree to receive additional information and to be contacted about other Merck products and services, health conditions, and topics in the future.

At any time, you can request that personal information about you be removed from the Merck contact list for additional materials and services by calling 1-888-776-8364. Unless you change your selections sooner, your permission will expire 1 year after Merck no longer provides disease information on ZOSTAVAX and specific medical options for ZOSTAVAX.

I wish to receive this additional information and to be contacted in the future. I understand that unless I change my selections sooner, my permission will expire 1 year after Merck no longer provides information on ZOSTAVAX.